Tetra commences PoC clinical trial of PPP003v for companion dogs
Category: #health  By Saipriya Iyer  Date: 2020-02-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

Tetra commences PoC clinical trial of PPP003v for companion dogs

Tetra Bio-Pharma Inc., a Canadian pharmaceutical firm that specializes in cannabinoid-derived drug therapy, has recently initiated a clinical study of synthetic cannabinoid therapy (PPP003v) for ophthalmic eye pain in veterinary setting.

Reportedly, Tetra joined forces with a veterinary ophthalmology team to commence the recruitment process for in-life phase proof of concept clinical study in companion dogs that suffer from indolent corneal ulcers. On February 21, the research team successfully treated their first dog. 

The clinical trial, which is approved by Health Canada, is developed to assess the tolerability, potential efficacy, and safety of PPP003v to ameliorate symptoms of ophthalmic eye disease in canines. For the record, indolent corneal ulcers are frequently observed in certain breeds of dogs. This type of ulcer comes as the most usual type of eye disorder in veterinarians and if left untreated, could cause severe inflammation, pain, vision loss, and scarring. 

According to reports, PPP003v is Tetra’s exclusive veterinary ocular solution for treating inflammation and ocular pain in pet animals. It was patented and developed by the pharma company’s ophthalmic sector and includes an optimally formulated non-controlled synthetic cannabinoid 2 receptor-selective agent for topical delivery to the eye.

Moreover, comprehensive preclinical studies have supported the Cannabinoid 2 receptor as an integral drug target for minimizing ocular pain and inflammation.

Speaking on the move, Dr. Guy Chamberland, CRO and CEO, Tetra BioPharma, said that the PPP003 series, which includes PPP003v, comes as an alluring prospect for the company as there is a massive unquenched medical need for severe inflammatory eye disorders. 

Moreover, these animal studies along with the veterinary program would offer crucial data, which could possibly be added as a chunk of the pre-clinical data essential for supporting the use of PPP003 in human clinical studies.

The company is extremely delighted to bag a validation from the U.S. FDA for its human ophthalmic research program and this marks as a significant milestone for Tetra, cites Dr. Chamberland.

Source Credit: https://finance.yahoo.com/news/tetra-bio-pharma-initiates-proof-130010929.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Regeneron begins late-stage trial of its coronavirus antibody cocktail
Regeneron begins late-stage trial of its coronavirus antibody cocktail
By Saipriya Iyer

Renowned American biopharmaceutical company, Regeneron Pharmaceuticals, has reportedly announced that it has started late-stage clinical trials of its proprietary antibody cocktail to assess its effectiveness in treati...

China completes 2 launches in 3-day span with Gaofen & Shiyan-6
China completes 2 launches in 3-day span with Gaofen & Shiyan-6
By Saipriya Iyer

China has recently launched its classified Shiyan-6 (02) satellite, following the launch of Gaofen, which is a ‘multimode’ Earth observation satellite, into orbit 2 days earlier. These two launches will mar...

Tetra Pak announces target to reach net-zero GHG emissions by 2030
Tetra Pak announces target to reach net-zero GHG emissions by 2030
By Saipriya Iyer

Tetra Pak, a food processing and packaging solutions provider, has recently announced its target to reach net-zero GHG (greenhouse gas) emissions in its operations by 2030.

The targ...